Medifast (MED) Depreciation & Amortization (CF) (2010 - 2026)

Medifast (MED) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $3.5 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 6.19% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.4 million (up 13.51% YoY) and the FY2025 annual result came in at $14.2 million, up 12.08% from the prior year.
• Depreciation & Amortization (CF) climbed to $3.5 million in Q1 2026, from $3.5 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $4.0 million in Q2 2025 to a low of $2.4 million in Q1 2022.
• A 5-year average of $3.2 million and a median of $3.3 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) surged 117.44% — and 2024, when it decreased 8.94%.
• Tracing MED's Depreciation & Amortization (CF) over 5 years: stood at $3.0 million in 2022, then gained by 13.51% to $3.4 million in 2023, then decreased by 5.01% to $3.2 million in 2024, then climbed by 8.79% to $3.5 million in 2025, then advanced by 0.52% to $3.5 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $3.5 million (Q1 2026), $3.5 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.